What smart money is saying about argenx
2 funds in our archive have pitched argenx, most recently Sands Capital Global Growth in December 2025.
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Get an email when a fund buys, sells or pitches it
Position history
Between Q2 2025 and Q3 2026, 11 fund letters reported a position in argenx, with 1 buy (opened or added) and 1 sell (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 0 | 0 |
| Q2 2026 | 5 | 0 | 1 | 0 |
| Q4 2025 | 2 | 1 | 0 | 1 |
| Q3 2025 | 2 | 0 | 0 | 0 |
| Q2 2025 | 1 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 11 positions · 2 moves
- September 2026
“Within the sector, Twist Bioscience, Argenx, 10x Genomics and West Pharma were among our stronger performers, partially offset by weakness in Veracyte and Ascendis Pharma.”
argenx - June 2026
“While the market primarily rewarded AI beneficiaries, our health care portfolio rose over 18% during Q2, outperforming the sector return within the index by roughly 16 percentage points.”
argenx - June 2026
“Eli Lilly and Company 3.70 BillionToOne, Inc. 1.06 argenx SE 0.98 Roivant Sciences Ltd. 0.95 Guardant Health, Inc. 0.90 Pharmaceutical company Eli Lilly and Company , currently best known for its diabetes and obesity GLP-1 therapies, contributed to performance as commercial execution and pipeline data reinforced investor confidence in the company's long-term leadership. All three major pharmacy benefit managers now cover Lilly's obesity portfolio, including its new daily oral GLP-1, Foundayo. This marks a reversal from last summer, when CVS Caremark provided preferred coverage for Novo Nordisk's Wegovy and raised concerns about a potential price war. The shift suggests that patients and physicians prefer Zepbound and are driving demand. Clinical trial data further reinforces our view that Lilly has one of the strongest next-generation metabolic pipelines in the industry. Phase 3 data showed retatrutide delivered weight loss in the high-20% range at higher doses and nearly 20% at lower doses, while maintaining excellent tolerability. We are also excited about eloralintide, where Phase 2 data showed Zepbound-like efficacy and tolerability, with combination data expected soon. Long term, we continue to view Lilly's portfolio as the gold standard in a category that we believe can exceed $150 billion. BillionToOne, Inc. is a diagnostics company that is disrupting the market with more accurate prenatal and oncology genetic tests. Today, the vast majority of the company's revenue is generated by UNITY, a unique prenatal test that can screen for recessive single-gene disorders from a maternal blood draw and identify fetal antigen status across both red blood cell and platelet antigens. Shares rose in the second quarter after the company reported robust first-quarter results (revenue up 84% year over year with 22% operating margins) and announced a meaningful expansion of commercial insurance coverage for its UNITY test and new UNITY Confirm product, which can replace amniocentesis or chorionic villus sampling to confirm a genetic diagnosis following a high-risk UNITY screening result. We continue to believe that BillionToOne's differentiated "quantitative counting template" technology enables more sensitive genetic testing. The company is making early headway in oncology with its SELECT therapy selection and RESPONSE therapy monitoring tests, which we think will be important future growth drivers. Biotechnology company argenx SE is best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions.”
argenx - June 2026
“In health care, we saw strong earnings and stock returns from biotech drug companies like Argenx and Ascendis Pharma, as well as from life sciences tools, diagnostics and drug- delivery-related businesses such as Twist Bioscience, West Pharmaceutical and Veracyte.”
argenx - June 2026
“Health care performance was more mixed, with a wide dispersion of outcomes within the portfolio. Argenx, West Pharmaceutical and Eli Lilly were among the strongest contributors, benefiting from company-specific profit cycles tied to differentiated therapies, improving demand visibility and solid execution.”
argenx - June 2026
Listed in Baron Fifth Avenue Growth Fund’s reported holdings.
argenx - New positionSands Capital Global GrowthDecember 2025
“In the fourth quarter Global Growth completed the purchases of AppLovin and argenx.”
argenx - December 2025
“In health care, Argenx, an immunology-focused biotechnology company, advanced on continued commercial execution and pipeline progress.”
argenx - September 2025
“Among our top contributors were Argenx, Insmed and Lattice Semiconductor.”
argenx - September 2025
“argenx SE is a global immunology company focused on improving the lives of patients suffering from severe autoimmune diseases.”
argenx - June 2025
“Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. Shares declined 6.8% after Q1 Vyvgart sales came in below elevated investor expectations, due to a combination of seasonal factors (such as insurance reverification) and higher Medicare Part D utilization and associated discounts. Our conversations with management and neurologists continue to reinforce Vyvgart’s value as an important treatment option with strong long-term growth potential.”
argenx
Also mentioned · 3
These funds discuss argenx as a competitor, benchmark or comparable, without disclosing a position in it.
- MentionedBaron Opportunity FundJune 2026
“The Fund’s Health Care investments performed well, with stand-out absolute and relative performance from Hinge Health, Inc. (digital musculoskeletal and physical therapy platform trailblazer), as well as a positive contribution from argenx SE (immunology and antibody-based medicine innovator).”
argenx - MentionedTimesSquare U.S. Mid Cap GrowthJune 2026
“argenx SE, a commercial stage biopharma company focused on developing treatments for autoimmune diseases, advanced 27%.”
argenx - MentionedBaron Opportunity StrategyJune 2026
“The Strategy’s Health Care investments performed well, with standout absolute and relative performance from Hinge Health, Inc. (digital musculoskeletal and physical therapy platform trailblazer), as well as a positive contribution from argenx SE (immunology and antibody-based medicine innovator).”
argenx
Fund coverage · 2 theses
- Sands Capital Global GrowthDecember 2025
argenx is a biotech focused on autoimmune diseases with a growing Vyvgart franchise, resilient pricing, and a pipeline that supports durable earnings and cash flow.
Read the full thesis - Baron Health Care FundJune 2025
Argenx SE is a biotechnology company developing Vyvgart, a leading FcRn inhibitor for autoimmune conditions, with strong long-term growth potential despite recent lower-than-expected sales due to seasonal factors.
Read the full thesis
Read every full thesis on argenx
Read all 2 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→